

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MICROBIOTICA, LIMITED,
Petitioner

v.

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
Patent Owner

Case PGR2023-00026
U.S. Patent No. 11,395,838

PATENT OWNER'S UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Patent Owner, Board of Regents, the University of Texas System (“Patent Owner”), files this Updated Exhibit List to accompany filing of Exhibit 2028, the transcript of a teleconference held between the Board and Parties on September 14, 2023.

Exhibit No.	Description
2001	Declaration of Wendy S. Garrett, M.D., Ph.D.
2002	<i>Curriculum Vitae</i> of Wendy S. Garrett, M.D., Ph.D.
2003	Nardinocchi <i>et al.</i> , “Interleukin-17 and interleukin-22 promote tumor expression in human nonmelanoma skin cancer,” <i>European Journal of Immunology</i> , 45:922-931 (March 2015)
2004	Vetizou <i>et al.</i> , “Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota,” <i>Science</i> , 350(6264):1079-1084 (November 2015)
2005	Sivan <i>et al.</i> , “Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti-PD-L1 efficacy,” <i>Science</i> , 350(6264):1084-1089 (November 2015)
2006	Ye <i>et al.</i> , “The Role and Regulation of Human Th17 Cells in Tumor Immunity,” <i>The American Journal of Pathology</i> , 182(1):10-20 (January 2013)
2007	He <i>et al.</i> , “IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid derived suppressor cells,” <i>Journal of Immunology</i> , 184(5):2281-2288 (March 2010)
2008	Brandt <i>et al.</i> , “An overview of fecal microbiota transplantation: techniques, indications, and outcomes,” <i>Gastrointestinal Endoscopy</i> , 78(2):240-249 (May 2013)

Exhibit No.	Description
2009	Vindigni <i>et al.</i> , “Fecal Microbiota Transplantation,” <i>Gastroenterology Clinics of North America</i> , 46(1):171-185 (March 2017)
2010	Youngster <i>et al.</i> , “Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent <i>Clostridium difficile</i> infection,” <i>BMC Medicine</i> , 14:134 (September 2016)
2011	Khan <i>et al.</i> , “Antioxidants Keep the Potentially Probiotic but Highly Oxygen-Sensitive Human Gut Bacterium <i>Faecalibacterium prausnitzii</i> Alive at Ambient Air,” <i>PLOS One</i> , 9(5):e96097 (May 2014)
2012	U.S. Patent Application Publication No. 2016/0193257 A1 to Honda <i>et al.</i> , published July 7, 2016 (“Tokyo”)
2013	Kuzu <i>et al.</i> , “Current State of Animal (Mouse) Modeling in Melanoma Research,” <i>Cancer Growth and Metastasis</i> , 8(Suppl 1):81-94 (October 2015)
2014	Dankort <i>et al.</i> , “Braf ^{V600E} cooperates with <i>Pten</i> loss to induce metastatic melanoma,” <i>Nature Genetics</i> , 41(5):544-552 (May 2009)
2015	Segata <i>et al.</i> , “Metagenomic biomarker discovery and explanation,” <i>Genome Biology</i> , 12(6):R60 (June 2011)
2016	Hadrup <i>et al.</i> , “Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment,” <i>Cancer Microenvironment</i> , 6(2):123-133 (August 2013)
2017	Peske <i>et al.</i> , “Control of CD8 T-cell Infiltration into Tumors by Vasculature and Microenvironment,” <i>Advanced Cancer Research</i> , 128:263-307 (June 2015)
2018	Chaput <i>et al.</i> , “Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab,” <i>Annals of Oncology</i> , 28(6):1368-1379 (June 2017)

Exhibit No.	Description
2019	Baruch <i>et al.</i> , “Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients,” <i>Science</i> , 371(6529):602-609 (February 2021)
2020	Davar <i>et al.</i> , “Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients,” <i>Science</i> , 371(6529):595-602 (February 2021)
2021	Wang <i>et al.</i> , “IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway,” <i>The Journal of Experimental Medicine</i> 206(7):1457-1464 (July 2009)
2022	Wang <i>et al.</i> , “IL-17 Enhances Tumor Development in Carcinogen-Induced Skin Cancer,” <i>Cancer Research</i> , 70(24):10112-10120 (December 2010)
2023	Villarino <i>et al.</i> , “Composition of the gut microbiota modulates the severity of malaria,” <i>Proceedings of the National Academy of Sciences</i> , 113(8):2235-2240 (February 2016)
2024	Xin <i>et al.</i> , “Isolation, identification and characterization of human intestinal bacteria with the ability to utilize chloramphenicol as the sole source of carbon and energy,” <i>FEMS Microbiology Ecology</i> , 82(3):703-712 (December 2012)
2025	Milojević, S., “Nature, Science, and PNAS Disciplinary profiles and impact,” <i>Scientometrics</i> , 123:1301-1315 (May 2020)
2026	“Management Team,” Microbiotica Limited, accessible at https://microbiotica.com/about/management-team/ , accessed August 21, 2023

Exhibit No.	Description
2027	“Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma,” Microbiotica Limited Press Release, April 12, 2023, accessible at https://microbiotica.com/microbiotica-announces-clinical-trial-collaboration-with-msd-to-evaluate-mb097-in-combination-with-keytruda-pembrolizumab-in-a-phase-1b-clinical-trial-in-melanoma/ , accessed August 21, 2023
2028	Transcript of teleconference between Board and Parties, September 14, 2023

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D., Esq.
Registration No. 39,967
Lead Attorney for Patent Owner

Date: September 21, 2023

1101 K Street NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER'S UPDATED EXHIBIT LIST** and **EXHIBIT 2028** were served in their entirety on September 21, 2023, upon the following parties via electronic mail:

Patrick D. McPherson (Lead Counsel)
DUANE MORRIS LLP
505 9th St. NW
Suite 1000
Washington, D.C. 20004
PDMcPherson@duanemorris.com

Christopher S. Kroon (Back-up Counsel)
DUANE MORRIS LLP
100 High Street
Suite 2400
Boston, MA 02110
CSKroon@duanemorris.com

Thomas J. Kowalski (Back-up Counsel)
DUANE MORRIS LLP
1540 Broadway
New York, NY 10036-4086
TJKowalski@duanemorris.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D., Esq.
Registration No. 39,967
Lead Attorney for Patent Owner

Date: September 21, 2023

1101 K Street NW, 10th Floor
Washington, DC 20005
(202) 371-2600